检索结果-南通市图书馆

Achieving high carrier mobility and low lattice thermal conductivity in GeTe-based alloys by cationic/anionic co-doping

在线全文

学校读者我要写书评

暂无评论

Rare Metals 2024年第6期43卷 2784-2795页

作者： xiao-qiang Wang xiao-Quan Hu jun-Yan lin Chu-bin li xiao-Tong yu Qi-Yong chen li-li xi Qi-Shuo Yang Han li Ji-Ye zhang Shuan-Kui li Kai guo School of Physics and Materials Science Guangzhou UniversityGuangzhou 510006China Research Center for Advanced Information Materials(CAIM) Huangpu Research&Graduate School of Guangzhou UniversitySino-Singapore Guangzhou Knowledge CityGuangzhou510555China School of Materials Science and Engineering Shanghai UniversityShanghai 200444China Materials Genome Institute Shanghai UniversityShanghai 200444China School of Mechanical and Mining Engineering University of QueenslandBrisbaneQLD 4072Australia Key Laboratory of Si-Based Information Materials&Devices and Integrated Circuits Design Department of Education of Guangdong ProvinceGuangzhou 510006China

TheⅣ-Ⅵcompound GeTe is considered as a promising alternative to the toxic PbTe for high-efficiency mid-temperature thermoelectric ***,pristine GeTe suffers from a high concentration of Ge vacancies,resulting in an excessively high hole concentration(>1×10^(21)cm^(-3)),which greatly limits its thermoelectric *** address this issue,CubiTe_(2)alloying is introduced to increase the formation energy of Ge vacancies in GeTe,thereby inhibiting the high carrier *** carrier scattering caused by the electronegativity difference between different elements is suppressed due to the similar electronegativity of Cu and Ge atoms.A relatively high hole mobility is obtained,which ultimately leads to a high power ***,by introducing Se as an alloying element at the anionic site in GeTe,dense point defects with mass/strainfield fluctuations are *** contributes to the strengthening of phonon scattering,thereby reducing the lattice thermal conductivity from 1.44 W·m^(-1)·K^(-1)for pristine GeTe to 0.28 W·m^(-1)·K^(-1)for Ge_(0.95)Cu_(0.05)bi_(0.05)Te_(0.9)Se_(0.15)compound at 623 K.

关键词： GeTe Carrier mobility CubiTe_(2)alloying Lattice thermal conductivity Thermoelectric properties

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci xiao-jun bi yuanjie bi Tianjian bian Fabrizio bianchi Thomas biekotter Michela biglietti Shalva bilanishvili Deng binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi junsong Cang guofu Cao Jianshe Cao Antoine Chance Xuejun Chang yue Chang Zhe Chang xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che yuzhi Che bin chen Danping chen fuqing chen fusan chen Gang chen guoming chen Hua-xing chen Huirun chen Jinhui chen Ji-yuan chen Kai chen Mali chen Mingjun chen Mingshui chen Ning chen Shanhong chen Shanzhen chen Shao-Long chen Shaomin chen Shiqiang chen Tianlu chen Wei chen xiang chen xiaoyu chen xin chen Xun chen Xurong chen Ye chen Ying chen yukai chen Zelin chen Zilin chen Gang chen Boping chen Chunhui chen Hok Chuen cheng Huajie cheng Shan cheng Tongguang cheng yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui xiaohao Cui Zhaoyuan Cui Brunella D'Anzi ling-yun Dai xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

抗菌药物临床应用信息化辅助决策系统专家共识

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华医院感染学杂志 2024年第12期34卷 1761-1766页

作者：高晓东张尧金文婷杜明梅陈璋璋陈佰义丁昉胡付品黄文祥李家斌李军李六亿李晓宇林丽开刘丁刘晓琳刘运喜刘正印倪语星王辉吴安华肖永红徐英春杨帆杨文杰杨小强俞云松张浩军赵彩彦赵烁卓超宗志勇李太生王贵强王明贵胡必杰复旦大学附属中山医院感染管理科上海200032 复旦大学附属中山医院感染科上海200032 中国人民解放军总医院第一医学中心疾病预防控制科北京100853 复旦大学附属中山医院药剂科上海200032 北京大学第一医院感染疾病科北京100034 复旦大学附属华山医院抗生素研究所上海200040 中国医学科学院北京协和医院感染科北京100730 中国医科大学附属第一医院感染病科辽宁沈阳110001 复旦大学附属中山医院医务处上海200032 重庆医科大学附属第一医院感染科重庆400042 江苏省人民医院感染科江苏南京210029 安徽医科大学第一附属医院感染科安徽合肥230022 北京大学第一医院感染管理科北京100034 武汉大学医院管理研究所湖北武汉430071 重庆市医院感染控制中心重庆408107 国家卫生健康委合理用药专家委员会北京100044 上海交通大学医学院附属瑞金医院感染管理科上海200025 北京大学人民医院检验科北京100044 中南大学湘雅医院感染科湖南长沙410008 浙江大学医学院附属第一医院传染病诊治国家重点实验室浙江杭州310003 中国医学科学院北京协和医学院北京协和医院检验科北京100730 天津市第一中心医院感染科天津300190 国家卫健委医院管理研究所药事管理研究部北京100044 浙江大学医学院附属邵逸夫医院感染科浙江杭州310003 甘肃省人民医院感染科甘肃兰州730099 河北医科大学第三医院感染科河北石家庄050051 国家卫生健康委医院管理研究所医疗服务与安全研究部北京100044 广州医科大学附属第一医院感染科广东广州510120 四川大学华西医院四川成都610041

目的规范我国抗菌药物临床应用信息化辅助决策系统的开发和应用,以促进我国抗菌药物管理的信息化建设.方法组织感染病学、感染防控、临床药学等抗菌药物临床应用管理小组的相关专家,在深入研究国内外抗菌药物临床应用信息化建设最新... 详细信息

目的规范我国抗菌药物临床应用信息化辅助决策系统的开发和应用,以促进我国抗菌药物管理的信息化建设.方法组织感染病学、感染防控、临床药学等抗菌药物临床应用管理小组的相关专家,在深入研究国内外抗菌药物临床应用信息化建设最新进展的基础上,结合我国临床实际需求,共同制定本共识.结果形成有关抗菌药物临床应用信息化辅助决策系统的17条专家共识.结论此专家共识供医疗机构抗菌药物临床应用管理小组在研发和应用信息系统进行临床决策支持时参考.

关键词：抗菌药物抗菌药物临床应用信息化辅助决策系统专家共识

同方期刊数据库

A practical community-based response strategy to interrupt Ebola transmission in sierra Leone, 2014–2015

在线全文

学校读者我要写书评

暂无评论

Infectious Diseases of Poverty 2016年第1期5卷 670-679页

作者： Zhong-Jie li Wen-xiao Tu xiao-Chun Wang guo-Qing Shi Zun-Dong Yin Hai-jun Su Tao Shen Da-Peng zhang Jian-Dong li Shan Lv Chun-li Cao Rui-Qian xie Hong-Zhou Lu Rong-Meng Jiang zheng Cao Zhi-Jie An Lei-Lei li Jie Xu Yan-Wen xiong Wei Zang Wei zhang Hong-Wei zhang Wen-Sen chen Hua ling Wen Xu Jian Cai Huan-Jin Luo Xue-Sheng xing Can-jun zheng qiang Wei xin-Xu li Mei li Hai Jiang li-Quan Deng Ming-Quan chen xiang Huo Feng Xu Xue-Hui Lai xi-chen Bai Long-Jie Ye Jian-Yi Yao Wen-Wu Yin Jiao-Jin Sun lin xiao fu-qiang liu xiao-qiang liu Hong-Wei Fan Zeng-qiang Kou Ji-Kun Zhou Hao zhang Da-xin Ni Thomas TSamba Qun li Hong-Jie yu yu Wang xiao-Feng liang Division of Infectious Disease Key Laboratory of Surveillance and Early-warning on Infectious DiseaseChinese Center for Disease Control and PreventionBeijingChina Public Health Emergency Center Chinese Center for Disease Control and PreventionBeijingChina National Center for AIDS/STD Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina Chinese Field Epidemiology Training Program Chinese Center for Disease Control and PreventionBeijingChina National Immunization Program Chinese Center for Disease Control and PreventionBeijingChina Bureau of Disease Prevention and Control National Health and Family Planning Commission of the People’s Republic of ChinaBeijingChina National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina National Institute of Parasitic Disease Chinese Center for Disease Control and PreventionShanghaiChina Chinese Center for Health Education BeijingChina Department of Infectious Diseases Shanghai Public Health Clinical CenterShanghaiChina Beijing Ditan Hospital Capital Medical UniversityBeijingChina Health News BeijingChina National Institute for Communicable Disease Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina Department of Training Chinese Center for Health EducationBeijingChina Center for Infectious Diseases Beijing Youan HospitalCapital Medical UniversityBeijingChina Infection Management The First Affiliated Hospital of Nanjing Medical UniversityNanjingChina Chongqing Municipal Center for Disease Control and Prevention ChongqingChina yunnan Provincial Center for Disease Control and Prevention KunmingChina Division of Infectious Disease Control and Prevention Zhejiang Provincial Center for Disease Control and PreventionHangzhouChina Guangdong Provincial Center for Disease Control and Prevention GuangzhouChina Division of Acute Infectious Disease Control and Prevention Hubei Provincial Center for Disease Control and PreventionW

Background:The Ebola virus disease spread rapidly in West Africa in 2014,leading to the loss of thousands of *** engagement was one of the key strategies to interrupt Ebola transmission,and practical community level measures needed to be explored in the field and tailored to the specific context of ***:First,community-level education on Ebola virus disease(EVD)prevention was launched for the community’s social mobilizers in six districts in Sierra Leone beginning in November ***,from January to May of 2015,in three pilot communities,local trained community members were organized to engage in implementation of EVD prevention and transmission interruption measures,by involving them in alert case report,contact tracing,and social *** epidemiological indicators of transmission interruption in three study communities were ***:A total of 6016 community social mobilizers from 185 wards were trained by holding 279 workshops in the six districts,and EVD message reached an estimated 631680 *** three pilot communities,72 EVD alert cases were reported,with 70.8%of them detected by trained local community members,and 14 EVD cases were finally *** tracing detected 64.3%of EVD *** median duration of community infectivity for the cases was 1 *** secondary attack rate was 4.2%,and no third generation of infection was *** health worker was infected,and no unsafe burial and noncompliance to EVD control measures were *** community-based measures were modeled to reduce 77 EVD cases,and the EVD-free goal was achieved four months earlier in study communities than whole country of Sierra ***: The community-based strategy of social mobilization and community engagement was effective in casedetection and reducing the extent of Ebola transmission in a country with weak health system. The successfullypractical experience to reduce the risk of Ebola transmission in the

关键词： Ebola virus disease Community engagement Health education Outbreak control

Lung-protective Ventilation in Patients with Brain Injury： A Multicenter Cross-sectional Study and Questionnaire Survey in China

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2016年第14期129卷 1643-1651页

作者： Xu-Ying Luo Ying-Hong Hu xiang-yuan Cao Yan Kang li-Ping liu Shou-Hong Wang Rong-guo yu xiang-You yu xia zhang Bao-Shan li Zeng-xiang Ma Yi-bing Weng Heng zhang De-Chang chen Wei chen Wen-Jin chen xiu-Mei chen bin Du Mei-li Duan Jin Hu yun-Feng Hoang Gui-jun Jia li-Hong li yu-Min liang bing-yu Qin xian-Dong Wang Jian xiong li-Mei Yan zheng-Ping Yang chen-Ming Dong Dong-xin Wang Qing-yuan Zhan Shuang-lin fu lin Zhao Qi-bing Huang Ying-Guang xie xiao-Bo Huang guo-bin zhang Wang-bin Xu yuan Xu Yaling liu He-ling Zhao Rong-Qing Sun Ming Sun Qing-Hong cheng xin Qu xiao-Feng Yang Ming Xu Zhong-Hua Shi Han chen Xuan He Yan-lin Yang Guang-qiang chen xiu-Mei Sun Jian-xin Zhou Department of Critical Care Medicine Beijing Tiantan Hospital Capital Medical University Beijing 100050 China Department of Critical Care Medicine Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang 310009 China Department of Critical Care Medicine General Hospital of Ningxia Medical University Yinchuan Ningxia 750004 China Department of Critical Care Medicine West China Hospital Sichuan University Chengdu Sichuan 610041 China Neurological Intensive Care Unit Beijing Tiantan Hospital Capital Medical University Beijing 100050 China Department of Critical Care Medicine Guangdong General Hospital Guangzhou Guangdong 510000 China Surgical Intensive Care Unit Fujian Province Hospital Fuzhou Fujian 350000 China Department of Critical Care Medicine First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang 830054 China Department of Critical Care Medicine Bethune International Peace Hospital Shijiazhuang Hebei 050000 China Department of Critical Care Medicine Yuncheng Central Hospital Yuncheng Shanxi 044000 China Department of Emergency and Critical Care Medicine Cangzhou People's Hospital Cangzhou Hebei 061000 China Department of Critical Care Medicine Beijing Luhe Hospital Capital Medical University Beijing 101100 China Department of Critical Care Medicine First Hospital of China Medical University Shenyang Liaoning 110000 China Department of Critical Care Medicine Shanghai Changzheng Hospital Shanghai 200000 China Department of Critical Care Medicine Beijing Shijitan Hospital Capital Medical University Beijing 100038 China Department of Critical Care Medicine Xuanwu Hospital Capital Medical University Beijing 100053 China Department of Critical Care Medicine Miyun County Hospital Beijing 100038 China Medical Intensive Care Unit Peking Union Medical College Hospital Beijing 101500 China Department of Critical Care Medicine Beijing Friendship Hospital Capital Medical University Beijing 100050 Chin

Background： Over the years, the mechanical ventilation （MV） strategy has changed worldwide. The aim of the present study was to describe the ventilation practices, particularly lung-protective ventilation （LPV）, among brain-injured patients in China. Methods： This study was a multicenter, 1-day, cross-sectional study in 47 Intensive Care Units （ICUs） across China. Mechanically ventilated patients （18 years and older） with brain injury in a participating ICU during the time of the study, including traumatic brain injury, stroke, postoperation with intracranial tumor, hypoxic-ischemic encephalopathy, intracranial infection, and idiopathic epilepsy, were enrolled. Demographic data, primary diagnoses, indications for MV, MV modes and settings, and prognoses on the 60th day were collected. Multivariable logistic analysis was used to assess factors that might affect the use of LPV. Results： A total of 104 patients were enrolled in the present study, 87 （83.7%） of whom were identified with severe brain injury based on a Glasgow Coma Scale 〈8 points. Synchronized intermittent mandatory ventilation （SIMV） was the most frequent ventilator mode, accounting for 46.2% of the entire cohort. The median tidal volume was set to 8.0 ml/kg （interquartile range [IQR], 7.0-8.9 ml/kg） of the predicted body weight; 50 （48.1%） patients received LPV. The median positive end-expiratory pressure （PEEP） was set to 5 cmH20 （IQR, 5-5 cmH20）. No PEEP values were higher than 10 cmH20. Compared with partially mandatory ventilation, supportive and spontaneous ventilation practices were associated with LPV. There were no significant differences in mortality and MV duration between patients subjected to LPV and those were not. Conclusions： Among brain-injured patients in China, SIMV was the most frequent ventilation mode. Nearly one-half of the brain-injured patients received LPV. Patients under supportive and spontaneous ventilation were more likely to receive LPV.

关键词： Brain Injury Epidemiology Lung-protective Ventilation Mechanical Ventilation

Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection:a randomized trial

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2021年第10期6卷 3009-3018页

作者： jun liu Dan-Dan li Wei Dong yu-Qi liu Yang Wu Da-Xuan Tang fu-Chun zhang Meng Qiu Qi Hua Jing-yu He jun li Bai Du Ting-Hai Du lin-lin Niu Xue-jun Jiang Bo Cui Jiang-bin chen Yang-Gan Wang Hai-Rong Wang Qin yu Jing He Yi-lin Mao xiao-Fang bin yue Deng yu-Dan Tian Qing-Hua Han Da-Jin liu li-Qin Duan Ming-jun Zhao Cui-Ying zhang Hai-Ying Dai Ze-Hua li Ying xiao You-Zhi Hu xiao-yu Huang Kun xing xin Jiang Chao-Feng liu Jing An Feng-Chun li Tao Tao Jin-Fa Jiang Ying Yang Yao-Rong Dong Lei zhang Guang fu Ying li Shu-Wei Huang li-Ping Dou Lan-jun Sun Ying-qiang Zhao Jie li yun xia jun liu Fan liu Wen-Jin He Ying li Jian-Cong Tan Yang lin Ya-bin Zhou Jian-Fei Yang guo-Qing Ma Hui-jun chen He-Ping liu Zong-Wu liu Jian-xiong liu xiao-Jia Luo xiao-Hong bin Ya-Nan yu Hai-xia Dang bing li Fei Teng Wang-Min Qiao xiao-Long Zhu bing-Wei chen Qi-Guang chen Chun-Ti Shen Yong-Yan Wang yun-Dai chen Zhong Wang Institute of Basic Research in Clinical Medicine China Academy of Chinese Medical SciencesBeijingChina Department of Cardiology Chinese PLA General HospitalBeijingChina Department of Cardiology Dongfang Hospital Affiliated to Beijing University of Chinese MedicineBeijingChina Department of Geratology Peking University Third HospitalBeijingChina Department of Cardiology Xuan Wu HospitalCapital Medical UniversityBeijingChina Department of Cardiology Guang'anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina Department of Cardiology First Affiliated Hospital of Henan University of Chinese MedicineZhengzhouHenanChina Department of Cardiology Wuhan University Renmin HospitalWuhanHubeiChina Department of Cardiology Wuhan University Zhongnan HospitalWuhanHubeiChina Affiliated Zhongshan Hospital of Dalian University DalianLiaoningChina Department of Cardiology Second Affiliated Hospital to Hunan University of Chinese MedicineChangshaHunanChina Department of Cardiology First Affiliated Hospital to Changchun University of Chinese MedicineChangchunJilinChina Department of Cardiology First Affiliated Hospital to Shanxi Medical UniversityTaiyuanShanxiChina Department of Cardiology Affiliated Hospital of Shanxi University of Chinese MedicineXianyangShanxiChina Department of Cardiology Changsha Central HospitalChangshaHunanChina Department of Cardiology Hubei Provincial Hospital of Traditional Chinese MedicineWuhanHubeiChina Department of Cardiology Shanxi Provincial People's HospitalXi'anShanxiChina Department of Cardiology Shanxi Province Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Xi'an City Hospital of Traditional Chinese MedicineXi'anShanxiChina Department of Cardiology Shanghai Tongji HospitalShanghaiChina Department of Cardiology Shanghai Municipal Hospital of Traditional Chinese MedicineShanghaiChina Department of Cardiology The First Hospital of ChangshaChangshaHunanChina Department of Cardiology Xinhua Hospi

It's a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in thedfferentiated populations with complex diseases,as stable coronary heart ***,in an adaptive,31-center,randomized,double-blind trial invoving 920 patients with moderate symptomatic stable angina treated by 14-day Danhong injection(DHI),a kind of polyphamacological drug with high quality control,or placebo(0.9%saline),with 76-day following-up,we firstly confrmed that DHl couldincrease the proportion of patients with clinically significant changes on angina-frequency assessed by Seattle Angina Questionnaire(ASAQ-AF220)(12.78%at Day 30,95%confidence interval[C]5.86-19.71%,P=0.0003,13.82%at Day 6C0,95%CI 6.82-20.82%,P=0.0001and 8.95%at Day 90,95%CI 2.06-15.85%,P=0.01).We also found that there were no significant differences in new-onset major vascularevents(P=0.8502)and serious adverse events(P=0.9105)between DHl and *** performing the RNA sequencing in 62 selectedpatients,we developed a systemic modular approach tp identfy differentilly expressed modules(DEMs)of DHI with the Z_(summay)valueless than 0 compared with the control group,calculated by weighted gene co-expression network analysis(WGCNA),and sketched out thebasic framework on a modular map with 25 functional modules targeted by ***,the effective therapeutic module(ETM),defined as the highest corelation value with the phenotype alteration(SAQ-AF,the change in SAQ-AF at Day 30 from baseline)calculatedby WGCNA,was identifed in the population with the best effect(ASAQ-AF240),which is related to anticoagulation and regulation ofcholesterol *** assessed the modular flexbility of this ETM using the global topological D value based on Euclidean distance,which is corelated with phenotype alteration(r^(2):0.8204,P=0.019)by linear *** study identified the ant-angina therapeuticmodule in the effective population treated by the multi-target

关键词： angina injection sketch

Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2013年第12期126卷 2276-2280页

作者： zheng Ying CAI Guang-yan chen xiang-mei fu Ping chen Jiang-hua DING xiao-qiang yu Xue-qing lin Hong-li liU Jian xiE Ru-juan WANG li-ning NI Zhao-hui liU fu-you YIN Ai-ping xiNG Chang-ying WANG li SHI Wei liU Jian-she HE Ya-ni DING guo-hua li Wen-ge WU Guang-li MIAO li-ning chen Nan SU Zhen MEI Chang-lin ZHAO Jiu-yang GU Yong BAI yun-kai LUO Hui-min lin Shan chen Meng-hua GONG li YANG Yi-bin YANG xiao-ping li Ying WAN Jian-xin WANG Nian-song li Hai-ying xi Chun-sheng HAO li XU Yan FANG Jing-ai liU bi-cheng li Rong-shan WANG Rong zhang Jing-hong WANG Jian-qin LOU Tan-qi SHAO Feng-min MEI Feng liU Zhi-hong yuAN Wei-jie SUN Shi-ren zhang ling ZHOU Chun-hua chen Qin-kai JIA Shun-lian GONG Zhi-feng GUAN Guang-ju xiA Tian ZHONG liang-bao Department of Nephrology State key Laboratory of Kidney Disease Chinese PLA General Hospital Beijing 100853 China Nephrology Institute of the Chinese People's liberation Army Chinese People's Liberation Army Key Laboratory of Nephrology Beijing 100853 China Department of Nephrology West China Hospital of Sichuan University Chengdu Sichuan 610041 China Department of Nephrology First Affiliated Hospital School of Medicine Zhejiang University Hangzhou Zhejiang 310003 China Department of Nephrology Zhongshan Hospital Fudan University Shanghai 200032 China Department of Nephrology First Affiiated Hospital of Sun Yat-sen University Guangzhou Guangdong 510080 China Department of Nephrology First Affiliated Hospital of Dalian Medical University Dalian Liaoning 116011 China Department of Nephrology First Affiliated Hospital of Xinjiang Medical University Urumqi Xinjiang 830054 China Department of Nephrology First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang 150001 China Department of Nephrology First Afftiated Hospital of China Medical University Shenyang Liaoning 110001 China Department of Nephrology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai 200025 China Department of Nephrology Second Xiangya Hospital Central South University Changsha Hunan 410000 China Department of Nephrology First Affiliated Hospital of Medical College Xi'an Jiaotong University Xi'an Shaanxi 710061 China Department of Nephrology First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) Nanjing Jiangsu 210029 China Department of Nephrology Sichuan Provincial People's Hospital Chengdu Sichuan 610072 China Department of Nephrology Guangdong Provincial People's Hospital Guangzhou Guangdong 510030 China Department of Nephrology Affliated Xiehe Hospital Tongji Medical College Huazhong Science and Technology University Wuhan Hubei 430022 China Department of Nephrology Daping Hospital Third Military Medi

Background Data on the epidemiology of hypertension in Chinese non-dialysis chronic kidney disease （CKD） patients are *** aim of the present study was to investigate the prevalence,awareness,treatment,and control of hypertension in the non-dialysis CKD patients through a nationwide,multicenter study in *** The survey was performed in 61 tertiary hospitals in 31 provinces,municipalities,and autonomous regions in China （except Hong Kong,Macao,and Taiwan）.Trained physicians collected demographic and clinical data and measured blood pressure （BP） using a standardized *** was defned as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg,and/or use of antihypertensive *** 〈140/90 mmHg and 〈130/80 mmHg were used as the 2 thresholds of hypertension *** multivariate logistic regression with adjustment for sex and age,we analyzed the association between CKD stages and uncontrolled hypertension in non-dialysis CKD *** The analysis included 8927 non-dialysis CKD *** prevalence,awareness,and treatment of hypertension in non-dialysis CKD patients were 67.3%,85.8%,and 81.0%,*** hypertensive CKD patients,33.1% and 14.1% had controlled BP to 〈140/90 mmHg and 〈130/80 mmHg,*** successive CKD stages,the prevalence of hypertension in non-dialysis CKD patients increased,but the control of hypertension decreased （P〈0.001）.When the threshold of BP 〈130/80 mmHg was considered,the risk of uncontrolled hypertension in CKD 2,3a,3b,4,and 5 stages increased 1.3,1.4,1.4,2.5,and 4.0 times compared with CKD 1 stage,respectively （P〈0.05）.Using the threshold of 〈140/90 mmHg,the risk of uncontrolled hypertension increased in advanced stages （P〈0.05）.Conclusions The prevalence of hypertension Chinese non-dialysis CKD patients was high,and the hypertension control was *** successive CKD stages,the risk of uncontrolled hypertension increased.

关键词： non-dialysis chronic kidney disease chronic kidney disease stages hypertension epidemiology

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao Yang yue-yi Deng Wei li Ya-ni He Zhao-hui Ni Yong-li Zhan Shan lin Zhi-yong guo jun Zhu Jing-ai Fang Xu-sheng liu li-hua Wang Rong Wang Nian-song Wang xiao-hong cheng li-qun He Ping Luo Shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru Jiang Hong-yu chen Wen-hu liu Hong-li lin Meng liang Lu Ma Ming chen li-qun Song Jian chen Qing Zhu Chang-ying xing yun li Ji-ning Gao Rong-shan li Ying li Hao zhang Ying Lu Qiao-ling Zhou jun-zhou fu qiang He Guang-yan Cai xiang-mei chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Pline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-bin ling Qiao-Nan Shan Xu-Yong Wei Rui Wang Chang-Ku Jia li Zhuang Tian Shen li-Min Ding Zhi-Dan Xu Lai-Bang Luo li-Bo Sun Guang-Ming li Tai-Shi Fang Nan Jiang Kun zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao Jiang qiang He lin-Sen Ye Yang Yang yu-Ting He Wen-Zhi guo liu-Gen Lan Xu-Yong Sun Dong chen Zhi-Shui chen Da-Wei Zhou Shao-jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi Bo Wang Jiang liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang lin Zhong Jing-Sheng Ma Qi-Gen li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-Hua zhang Xuan Wang Zi-qiang li Mu-Jian Teng jun-Jie li Wen-Tao Jiang Jian-Hua li Quan-Bao zhang Ning-Qi Zhu zheng-xin Wang Kang He qiang xia Shao-Hua Song Zhi-Ren fu Wei Qiu guo-yue Lv Rui-Peng Song Ji-Zhou Wang zheng Wang Jian Zhou Gang chen Ying-Peng Zhao li li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si bin xie xiao-Shun He Zhi-Yong guo Shu-Sen zheng xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma liver transplantation Conversion